Kinnari Patel
Präsident bei ROCKET PHARMACEUTICALS, INC.
Vermögen: 11 Mio $ am 31.05.2024
Aktive Positionen von Kinnari Patel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | Geschäftsführer | 04.01.2018 | - |
Technik-/Wissenschafts-/F&E-Leiter | 27.03.2024 | - | |
Präsident | - | - |
Karriereverlauf von Kinnari Patel
Ehemalige bekannte Positionen von Kinnari Patel
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Geschäftsführer | 01.01.2018 | 01.02.2021 |
General Counsel | 01.04.2016 | 01.12.2017 | |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.11.2010 | 01.04.2014 |
Ausbildung von Kinnari Patel
The Leonard N Stern School of Business | Masters Business Admin |
University of the Sciences in Philadelphia | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Chief Operating Officer | 2 |
Chief Tech/Sci/R&D Officer | 1 |
President | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ROCKET PHARMACEUTICALS, INC. | Health Technology |
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Private Unternehmen | 1 |
---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Kinnari Patel
- Erfahrung